Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel VT Catenacci; Niall C Tebbutt; Irina Davidenko; Andre M Murad; Salah-Eddin Al-Batran; David H Ilson; Sergei Tjulandin; Evengy Gotovkin; Boguslawa Karaszewska; Igor Bondarenko; Mohamedtaki A Tejani; Anghel A Udrea; Mustapha Tehfe; Ferdinando De Vita; Cheryl Turkington; Rui Tang; Agnes Ang; Yilong Zhang; Tien Hoang; Roger Sidhu; David Cunningham

Journal article

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel VT Catenacci, Niall C Tebbutt, Irina Davidenko, Andre M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki A Tejani, Anghel A Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu Show all

LANCET ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2017

DOI: 10.1016/S1470-2045(17)30566-1

Abstract

BACKGROUND: Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy, safety, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine, and to assess potential biomarkers, in patients with advanced MET-positive gastric or gastro-oesophageal junction adenocarcinoma. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 study was done at 152 centres in 27 countries. We recruited adults (aged ≥18 years) with unresectable locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperat..

View full abstract